Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.35 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 11/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 11/20 | 0.40 |
| ▸ | LMNA | P02545 | 5/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL6422672 | 0.86 | MTNR1A (0.41) | MTNR1AMTNR1BKDM4ECYP1A2CYP2D6 | |
| Citric Acid SCHEMBL3253261 | 0.84 | MTNR1A (0.59) | MTNR1AMTNR1BKDM4ECYP1A2CYP2D6 | |
| Citric Acid SCHEMBL3248462 | 0.76 | MTNR1A (0.57) | MTNR1AMTNR1BLMNAKDM4ECYP1A2 | |
| Citric Acid SCHEMBL3248609 | 0.76 | MTNR1A (0.55) | MTNR1AMTNR1BKDM4ECYP1A2CYP2D6 | |
| SCHEMBL6425851 | 0.75 | MTNR1A (0.38) | MTNR1AMTNR1BKDM4ECYP1A2CYP2D6 | |
| Oxalic Acid SCHEMBL3250917 | 0.72 | MTNR1A (0.67) | MTNR1AMTNR1BKDM4ECYP1A2CYP2D6 | |
| Citric Acid SCHEMBL5101053 | 0.71 | TACR1 (0.41) | LMNAKDM4ECYP1A2CYP2D6MEN1 | |
| Citric Acid SCHEMBL3253262 | 0.71 | MTNR1A (0.58) | MTNR1AMTNR1BKDM4ECYP1A2CYP2D6 | |
| Citric Acid SCHEMBL3248466 | 0.70 | MTNR1A (0.57) | MTNR1AMTNR1BKDM4ECYP1A2CYP2D6 | |
| Maleic Acid SCHEMBL3250853 | 0.70 | MTNR1A (0.64) | MTNR1AMTNR1BKDM4ECYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050203103-A1 | Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203103-A1 | Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | TPH1, HTR1A, HTR7 | MEN1 3998/4885ESR1 1952/4885ESR2 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.